Organophosphorus Compounds
"Organophosphorus Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds that contain phosphorus as an integral part of the molecule. Included under this heading is broad array of synthetic compounds that are used as PESTICIDES and DRUGS.
| Descriptor ID |
D009943
|
| MeSH Number(s) |
D02.705
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Organophosphorus Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organophosphorus Compounds".
This graph shows the total number of publications written about "Organophosphorus Compounds" by people in this website by year, and whether "Organophosphorus Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 4 | 0 | 4 |
| 2020 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Organophosphorus Compounds" by people in Profiles.
-
Evaluating the Antiproliferative Effects of Tri(2-Furyl)- and Triphenylphosphine-Gold(I) Pyridyl- and Pyrimidine-Thiolate Complexes. Biomolecules. 2026 Jan 15; 16(1).
-
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status. Clin Lung Cancer. 2025 Nov; 26(7):e503-e513.e11.
-
Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis. Gut. 2020 11; 69(11):1928-1938.
-
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol. 2016 Dec; 17(12):1683-1696.
-
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models. Clin Cancer Res. 2016 Nov 15; 22(22):5527-5538.
-
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice. Oncotarget. 2016 May 17; 7(20):29011-22.
-
Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase. J Med Chem. 2016 05 26; 59(10):4948-64.
-
Molybdenum cofactor deficiency. Mol Genet Metab. 2016 Jan; 117(1):1-4.
-
Modeling studies with Helicobacter pylori octaprenyl pyrophosphate synthase reveal the enzymatic mechanism of trans-prenyltransferases. Int J Biochem Cell Biol. 2012 Dec; 44(12):2116-23.
-
Anaphylactic reaction to etoposide phosphate. Pediatr Blood Cancer. 2012 Oct; 59(4):765.